PMID- 10903958
OWN - NLM
STAT- MEDLINE
DCOM- 20000913
LR  - 20220318
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 130
IP  - 6
DP  - 2000 Jul
TI  - Beneficial effects of n-acetylcysteine on ischaemic brain injury.
PG  - 1219-26
AB  - 1. Nitric oxide (NO), peroxynitrite, formed from NO and superoxide anion, poly 
      (ADP-ribole) synthetase have been implicated as mediators of neuronal damage 
      following focal ischaemia. Here we have investigated the effects of 
      n-acetylcysteine (NAC) treatment in Mongolian gerbils subjected to cerebral 
      ischaemia. 2. Treatment of gerbils with NAC (20 mg kg(-1) 30 min before 
      reperfusion and 1, 2 and 6 h after reperfusion) reduced the formation of 
      post-ischaemic brain oedema, evaluated by water content. 3. NAC also attenuated 
      the increase in the brain levels of malondialdehyde (MDA) and the increase in the 
      hippocampus of myeloperoxidase (MPO) caused by cerebral ischaemia. 4. Positive 
      staining for nitrotyrosine was found in the hippocampus in Mongolian gerbils 
      subjected to cerebral ischaemia. Hippocampus tissue sections from Mongolian 
      gerbils subjected to cerebral ischaemia also showed positive staining for poly 
      (ADP-ribose) synthetase (PARS). The degree of staining for nitrotyrosine and for 
      PARS were markedly reduced in tissue sections obtained from animals that received 
      NAC. 5. NAC treatment increased survival and reduced hyperactivity linked to 
      neurodegeneration induced by cerebral ischaemia and reperfusion. 6. Histological 
      observations of the pyramidal layer of CA1 showed a reduction of neuronal loss in 
      animals that received NAC. 7. These results show that NAC improves brain injury 
      induced by transient cerebral ischaemia.
FAU - Cuzzocrea, S
AU  - Cuzzocrea S
AD  - Institute of Pharmacology, School of Medicine, University of Messina, Torre 
      Biologica, Policlinico Universitario Via C. Valeria, Italy. 
      salvator@imeuniv.unime.it
FAU - Mazzon, E
AU  - Mazzon E
FAU - Costantino, G
AU  - Costantino G
FAU - Serraino, I
AU  - Serraino I
FAU - Dugo, L
AU  - Dugo L
FAU - Calabro, G
AU  - Calabro G
FAU - Cucinotta, G
AU  - Cucinotta G
FAU - De Sarro, A
AU  - De Sarro A
FAU - Caputi, A P
AU  - Caputi AP
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Free Radical Scavengers)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 3604-79-3 (3-nitrotyrosine)
RN  - 42HK56048U (Tyrosine)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/*pharmacology
MH  - Animals
MH  - Brain/drug effects/metabolism/pathology
MH  - Brain Edema/pathology/prevention & control
MH  - Brain Ischemia/metabolism/physiopathology/*prevention & control
MH  - Free Radical Scavengers/*pharmacology
MH  - Gerbillinae
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Motor Activity/drug effects
MH  - Nitric Oxide/metabolism
MH  - Peroxidase/drug effects/metabolism
MH  - Poly(ADP-ribose) Polymerases/drug effects/metabolism
MH  - Reperfusion Injury/metabolism/physiopathology/*prevention & control
MH  - Time Factors
MH  - Tyrosine/analogs & derivatives/drug effects/metabolism
PMC - PMC1572181
EDAT- 2000/07/25 11:00
MHDA- 2000/09/19 11:01
PMCR- 2001/07/01
CRDT- 2000/07/25 11:00
PHST- 2000/07/25 11:00 [pubmed]
PHST- 2000/09/19 11:01 [medline]
PHST- 2000/07/25 11:00 [entrez]
PHST- 2001/07/01 00:00 [pmc-release]
AID - 0703421 [pii]
AID - 10.1038/sj.bjp.0703421 [doi]
PST - ppublish
SO  - Br J Pharmacol. 2000 Jul;130(6):1219-26. doi: 10.1038/sj.bjp.0703421.